HC Wainwright Reaffirms Buy Rating for Silence Therapeutics (NASDAQ:SLN)

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They presently have a $75.00 price target on the stock. HC Wainwright also issued estimates for Silence Therapeutics’ FY2030 earnings at ($1.95) EPS.

SLN has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Thursday, January 22nd. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, March 2nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Silence Therapeutics in a report on Thursday, March 5th. Five analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $34.50.

Silence Therapeutics Stock Performance

Shares of SLN opened at $6.90 on Friday. Silence Therapeutics has a fifty-two week low of $1.97 and a fifty-two week high of $7.83. The firm has a 50-day simple moving average of $5.38 and a 200-day simple moving average of $5.81. The company has a market capitalization of $325.89 million, a price-to-earnings ratio of -3.69 and a beta of 1.32.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.07. Silence Therapeutics had a negative return on equity of 101.71% and a negative net margin of 15,851.88%.The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $2.19 million. Equities research analysts forecast that Silence Therapeutics will post -1.77 EPS for the current year.

Institutional Investors Weigh In On Silence Therapeutics

Several hedge funds have recently made changes to their positions in SLN. EHP Funds Inc. purchased a new position in Silence Therapeutics during the third quarter worth about $55,000. Beacon Pointe Advisors LLC purchased a new stake in Silence Therapeutics in the 2nd quarter valued at about $67,000. XTX Topco Ltd purchased a new stake in Silence Therapeutics in the 4th quarter valued at about $71,000. China Universal Asset Management Co. Ltd. grew its holdings in Silence Therapeutics by 65.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after buying an additional 5,421 shares during the period. Finally, Evelyn Partners Investment Management Services Ltd increased its stake in shares of Silence Therapeutics by 481.3% during the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 14,334 shares of the company’s stock valued at $77,000 after acquiring an additional 11,868 shares during the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.